Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

Harrington, K. J., Vile, R. G., Melcher, A., Chester, John D. ORCID: https://orcid.org/0000-0002-7830-3840 and Pandha, H. 2010. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine & Growth Factor Reviews 21 (2-3) , pp. 91-98.

Full text not available from this repository.

Abstract

It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with relapsed/metastatic cancers. By drawing on lessons learned during the development of other biological therapies, such as monoclonal antibodies and targeted small molecule inhibitors, we are now in a position to chart the course of the next wave of trials that will go beyond the phase I studies of safety and feasibility. In this article we review our approach to the development of oncolytic viruses as cancer therapeutics. In doing so, we emphasise the fact that this process is modular and involves multiple iterative steps between the laboratory and the clinic. Ultimately, at least in the medium term, the future of oncolytic virotherapy lies in combination regimens with standard anti-cancer agents such as radiation and chemotherapy

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	Oncolytic virus; Reovirus; Chemotherapy; Radiotherapy; Clinical trial
Publisher:	Elsevier
ISSN:	1359-6101
Last Modified:	25 Oct 2022 08:21
URI:	https://orca.cardiff.ac.uk/id/eprint/52516

Citation Data

Cited 73 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item